Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

×



Make an Appointment

Piasi Relative Ofantore n& Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

**History** 

Equality, diversity & inclusion

Annual report

Give to MSK

for most women with advanced ovarian cancer.

The study, conducted by Deborah K. Armstrong, MD, an assistant professor at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, and her colleagues, builds upon evidence from eight other clinical trials — including those conducted at Memorial Sloan Kettering Cancer Center (MSKCC) — showing an overall survival period of approximately one year for women treated with IP chemotherapy after "optimal debulking" — surgery to remove most, if not all, of the cancer in the abdomen.

Based on this overwhelming evidence, the <u>National Cancer Institute</u> (NCI) will issue a clinical announcement on January 5 encouraging the administration of a combination of IV and IP chemotherapy to treat women with advanced ovarian cancer, who have undergone optimal surgical debulking.

After pioneering the first clinical trials of IP chemotherapy in the late 1980s, MSKCC is one of the most experienced centers with the largest volume of patients who have undergone the procedure. The Center has been using IP chemotherapy as a standard of care based on Dr. Armstrong's presentation at the <u>American Society of Clinical Oncology's</u> annual meeting in May 2005 and research conducted at MSKCC.

Patients who have undergone the procedure and gynecological oncologists experienced in performing it are available for interview.



- About MSK
ADOUL INDIC
About us
<u>Careers</u>
Giving.■
- Cancer Care
Adult cancer types
Child & teen cancer types
Integrative medicine
Nutrition & cancer
Find a doctor
- Research & Education
Sloan Kettering Institute
Gerstner Sloan Kettering Graduate School ■
Graduate medical education
MSK Library.  ■
Communication preferences  Cookie preferences
Legal disclaimer
Accessibility statement
Privacy policy
Price transparency
Public notices
© 2024 Memorial Sloan Kettering Cancer Center